Crisis in infectious diseases: Time for a new paradigm?

Clinical Infectious Diseases

Volumn 23, Issue 4, 1996, Pages 790-794

  Casadevall, Arturo ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; CEPHALOSPORIN DERIVATIVE; CYTOKINE; ETHYLHYDROCUPREINE; GROWTH FACTOR; HAEMOPHILUS INFLUENZAE VACCINE; HEPATITIS B VACCINE; ISONIAZID; METICILLIN; NEW DRUG; PENICILLIN DERIVATIVE; PENTAMIDINE; POLIOMYELITIS VACCINE; SULFONAMIDE; VANCOMYCIN; VIRUS VACCINE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; DRUG RESEARCH; ENTEROCOCCUS; GRAM NEGATIVE BACTERIUM; HOSPITAL INFECTION; HOST RESISTANCE; IMMUNE DEFICIENCY; LOBAR PNEUMONIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MYCOBACTERIUM TUBERCULOSIS; MYCOSIS; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS;

EID: 0029745684     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/23.4.790     Document Type: Review

References (15)

1. Cohen ML. Epidemiology of drug resistance: implications for a postantimicrobial era. Science 1992;257:1050-5.
2. Neu HC. The crisis in antibiotic resistance. Science 1992;257:1064-73.
3. Kunin CM. Resistance to antimicrobial drugs - a worldwide calamity. Ann Intern Med 1993;118:557-61.
4. Berkelman RL, Hughes JM. The conquest of infectious diseases: who are we kidding? [editorial]. Ann Intern Med 1993;119:426-8.
5. Travis J. Reviving the antibiotic miracle? Science 1994;264:360-2.
6. Armstrong D. History of opportunistic infection in the immunocompromised host. Clin Infect Dis 1993;17(suppl 2):S318-21.
7. Armstrong D, Neu H, Peterson LR, Tomasz A. The prospects of treatment failure in the chemotherapy of infectious diseases in the 1990s. Microbial Drug Resistance 1995;1:1-4.
8. Jawetz E. Antimicrobial therapy. Ann Rev Microbiol 1956;10:85-114.
9. Finland M. Empiric therapy for bacterial infections: the historical perspective. Rev Infect Dis 1983;5(suppl):S2-8.
10. Casadevall A, Scharff MD. "Serum therapy" revisited: animal models of infection and the development of passive antibody therapy. Antimicrob Agents Chemother 1994;38:1695-1702.
11. Casadevall A, Scharff MD. Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis 1995;21:150-61.
12. Anonymous. Bacteriophage therapy [editorial]. JAMA 1933;100:1431-2.
13. Moore HF, Chesney AM. A further study of ethylhydrocuprein (optochin) in the treatment of acute lobar pneumonia. Arch Intern Med 1918;21: 661-81.
14. Fraser VJ, Jones M, Dunkel J, Stofer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992;15:414-21.
15. Silver LL, Bostian KA. Discovery and development of new antibiotics: the problem of antibiotic resistance. Antimicrob Agents Chemother 1993;37:377-83.